The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1 g/ml for 10 species of Enterobacteriaceae (n ‫؍‬ 351), from 0.03 to 0.12 g/ml for oxacillin-susceptible staphylococci (n ‫؍‬ 119), from 4 to 32 g/ml for oxacillin-resistant staphylococci (n ‫؍‬ 64), from <0.008 to 0.06 g/ml for penicillin-susceptible streptococci (n ‫؍‬ 132), and from 1 to 4 g/ml for penicillin-resistant streptococci (n ‫؍‬ 51). Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.
The synthesis of new carbapenems remains an area of intense research because of the broad-spectrum antibacterial activity of this chemical class (6-9, 11, 12) . Doripenem (formerly S-4661) is an investigational parenteral 1␤-methlycarbapenem, originally discovered by Shionogi & Co., Ltd. (Osaka, Japan) (1) , that is currently being developed in the United States by Peninsula Pharmaceuticals, Inc. (Alameda, Calif.) for the treatment of hospitalized patients with serious systemic bacterial infections. Preliminary reports indicate that doripenem has activity against a broad spectrum of bacterial pathogens (6, 9, 11; , that it is not hydrolyzed by renal dehydropeptidase I like imipenem (2) , and that it does not promote the release of endotoxin (10) . The objectives of the present study were to investigate the in vitro activity of doripenem against a collection of clinically relevant gram-negative and gram-positive pathogens and to compare the activity of doripenem with the activities of other carbapenems, broad-spectrum cephalosporins, and piperacillin-tazobactam.
(Part of this research was presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., 14 to 17 September 2003.)
Isolates tested in the present study were selected from the isolate repository maintained by Focus Technologies (Herndon, Va.) based upon the isolates' species or group identity and their antimicrobial susceptibility testing phenotype; isolates were chosen irrespective of the age of the patient (Ͻ1 to 98 years), the specimen source (respiratory, wound, urine, or blood) from which they were isolated, or any other patient demographic parameter. All isolates tested in the present study were collected in U.S. clinical microbiology laboratories from 1999 to 2003. In total, 815 isolates were tested, of which 381 were gram-negative isolates and 434 were gram-positive isolates. Each isolate was taken from frozen stock (Ϫ70°C) and subcultured twice onto sheep blood agar; the identity of each isolate was confirmed by using standard clinical laboratory methods applicable to each species or organism group (3).
Antimicrobial susceptibility testing was performed in accordance with the recommended procedures of the National Committee for Clinical Laboratory Standards (NCCLS) (4) by using frozen broth microdilution panels prepared by TREK Diagnostics (Cleveland, Ohio). All isolates were tested against cefepime, ceftriaxone, doripenem, ertapenem, imipenem, meropenem, and piperacillin-tazobactam. Additional antimicrobial agents were tested to confirm antimicrobial susceptibility testing phenotypes and for reference. These agents varied with bacterial species or organism group as follows: gram-negative bacteria were also tested against ampicillin, amoxicillin-clavulanate, aztreonam, ceftazidime, and ciprofloxacin; staphylococci and enterococci were also tested against oxacillin, levofloxacin, and vancomycin; and streptococci were also tested against penicillin, azithromycin, and levofloxacin. Isolates were defined as susceptible, intermediate, or resistant to antimicrobial agents according to NCCLS standard M100-S13 (5). Extended-spectrum ␤-lactamase (ESBL) confirmatory testing was performed by using the NC-CLS recommended method for isolates of Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca (5).
The doripenem MICs at which 90% of the strains were inhibited (MIC 90 ) ranged from 0.03 to 0.5 g/ml for all Enterobacteriaceae tested, with the exception of Proteus mirabilis (MIC 90 , 1 g/ml) ( Table 1 ). The MICs of doripenem for the isolates of Enterobacteriaceae tested were similar to the MICs of ertapenem and meropenem, while imipenem MICs were approximately 2 to 4 doubling dilutions higher than the MICs of the other three carbapenems (Fig. 1) . The MICs at which 50% of the strains were inhibited, MIC 90 s, modal MICs, and MIC ranges of doripenem for ESBL-negative and ESBL-positive E. coli and K. pneumoniae were similar; the MICs of doripenem for ceftazidime-intermediate and -resistant isolates of other Enterobacteriaceae were identical or 1 to 2 doubling As demonstrated for ertapenem, imipenem, and meropenem, doripenem showed limited activity against enterococci (Table 1) . Doripenem was more active against both vancomycin-resistant and vancomycin-susceptible isolates of Enterococcus faecalis (MIC 90 , 8 g/ml) than against Enterococcus faecium (MIC 90 , Ͼ32 g/ml).
Doripenem was more active against oxacillin-susceptible isolates (MIC 90 s, 0.03 to 0.12 g/ml) than against oxacillin-resistant isolates (MIC 90 s, 4 to 32 g/ml) of Staphylococcus aureus, Staphylococcus epidermidis, and coagulase-negative staphylococci other than S. epidermidis ( Table 1 ). The MICs of doripenem for staphylococci were similar to those of imipenem and lower than those of ertapenem and meropenem. The MICs of all of the carbapenems including doripenem (Fig. 2) and the other ␤-lactams tested were higher for oxacillin-resistant staphylococci than for oxacillin-susceptible staphylococci. Doripenem, ertapenem, imipenem, and meropenem MIC 90 s were all Յ0.008 g/ml for Streptococcus pyogenes (Table 1) . For Streptococcus agalactiae, the MIC 90 s of doripenem (0.015 g/ml) and imipenem (0.015 g/ml) were lower than those of ertapenem (0.06 g/ml) and meropenem (0.03 to 0.06 g/ml). 
